Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children

Antiviral Therapy

Volumn 11, Issue 4, 2006, Pages 439-445

  Van Der Lee, Manon ^a   Verweel, Gwenda ^b   De Groot, Ronald ^a   Burger, David ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC 50; IN VITRO STUDY; MALE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; LAMIVUDINE; MALE; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 33745770427     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Summary of product characteristics Kaletra®. In Committee for Proprietary Medicinal Products. European Public Assessment Report (EPAR). Kaletra soft capsules. The European Agency for the Evaluation of Medicinal Products; 2001.
2. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004; 18:775-779.
3. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22:216-224.
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
5. Negredo E, Molto J, Munoz-Moreno JA, et al. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antiviral Therapy 2004; 9:335-342.
6. Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis 2003; 36:1186-1190.
7. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002; 36:1193-1203.
8. Cvetkovic R, Goa K. Lopinavir/ritonavir: a review of its use in the management of HIV infection. DRUGS 2003; 63:769-802.
9. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 2004; 189:265-272.
10. Droste JAH, Verweij-van Wissen CPWGM, Burger DM. Simultaneous Determination of the HIV Drugs Indinavir, Amprenavir, Saquinavir, Ritonavir, Lopinavir, Nelfinavir, the Nelfinavir hydroxymetabolite M8 and Nevirapine in Human Plasma by Reversed Phase High Performance Liquid Chromatography. Therapeutic Drug Monitoring 2003; 25:393-399.
11. Anonymous. Optimising TDM in HIV clinical care. A practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents, 2003. Available at: http://www.HIVpharmacology.com.
12. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:350-359.
13. Gibaldi M. Compartmental and noncompartmental pharmacokinetics. In Biopharmaceutics and Clinical Pharmacokinetics, 4th Edn 1991; pp. 14-23. Philadelphia, London: Lea & Febiger.
14. La Porte CJ, Schippers EF, Van Der Ende ME, et al. Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications. AIDS 2005; 19:1105-1107.
15. King JR, Kimberlin DW, Aldrovandi GM, Acosta EP. Antiretroviral pharmacokinetics in the paediatric population: a review. Clin Pharmacokinet 2002; 41:1115-1133.
16. Fraaij PL, Rakhmanina N, Burger DM, De Groot R. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit 2004; 26:122-126.
17. Bergshoeff AS, Fraaij PL, Van Rossum AM, et al. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Ther 2003; 8:215-222.
18. Floren LC, Wiznia A, Hayashi S, et al. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics 2003; 112:e220-e227.